Reaction
Neuroblastoma Recurrent reporting signals
As of the last recalculation, Neuroblastoma Recurrent appears in 199 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is TEMOZOLOMIDE (PRR 232.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Temozolomide | 38 | 232.9 | 233.3 |
| Melphalan | 34 | 188.3 | 188.6 |
| Filgrastim | 50 | 185.4 | 185.6 |
| Melphalan Hydrochloride | 36 | 183.1 | 183.4 |
| Methadone Hydrochloride | 16 | 168.1 | 168.3 |
| Dexamethasone Sodium Phosphate | 15 | 167.0 | 167.2 |
| Hydroxyzine Hydrochloride | 16 | 138.3 | 138.5 |
| Hydroxyzine Hydrochloride Oral | 16 | 138.3 | 138.5 |
| Etoposide | 59 | 118.9 | 119.0 |
| Irinotecan Hydrochloride | 12 | 103.8 | 103.9 |
| Hydroxyzine | 37 | 99.5 | 99.5 |
| Ifosfamide | 17 | 90.4 | 90.5 |
| Cannabidiol | 17 | 83.0 | 83.0 |
| Isotretinoin | 15 | 34.2 | 34.2 |
| Pegfilgrastim | 23 | 27.4 | 27.4 |